Monoclonal Antibody to Chitinase-3-like Protein 1 (CHI3L1)
GP39; CHI3-L1; YKL40; Chondrex; Chitinase 3-Like 1; Chondrocyte Protein YKL40; 39 kDa synovial protein
- Product No.MAB463Hu23
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourceMonoclonal antibody preparation
- HostMouse
- Potency (Clone Number)C3
- Ig Isotype IgG1 Kappa
- PurificationProtein A + Protein G affinity chromatography
- LabelNone
- Immunogen RPB463Hu01-Recombinant Chitinase-3-like Protein 1 (CHI3L1)
- Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
- TraitsLiquid
- Concentration1mg/ml
- Organism Species Moren/a
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - Downloadn/a
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 107
For more details, please contact local distributors! US$ 250 US$ 357 US$ 893 US$ 3570
SPECIFITY
The antibody is a mouse monoclonal antibody raised against CHI3L1. It has been selected for its ability to recognize CHI3L1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- Antibody Labeling Customized Service
- Protein A/G Purification Column
- Staining Solution for Cells and Tissue
- Positive Control for Antibody
- Tissue/Sections Customized Service
- Phosphorylated Antibody Customized Service
- Western Blot (WB) Experiment Service
- Immunohistochemistry (IHC) Experiment Service
- Immunocytochemistry (ICC) Experiment Service
- Flow Cytometry (FCM) Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Immunofluorescence (IF) Experiment Service
- Buffer
- DAB Chromogen Kit
- SABC Kit
- Long-arm Biotin Labeling Kit
- Real Time PCR Experimental Service
Magazine | Citations |
Molecular and Cellular Biochemistry | Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Pubmed:25421412 |
BMC Pulmonary Medicine | YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment Pubmed:25578181 |
International Journal of Rheumatic Diseases | Assessment of pulsed electromagnetic field therapy with Serum YKL‐40 and ultrasonography in patients with knee osteoarthritis PubMed: 25955771 |
Respiratory Research | YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling Pubmed:27013031 |
United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
Chronic obstructive pulmonary disease (COPD)--from biomarkers to clinical phenotypes ISBN:978-951-51-4039-5 | |
EYE | YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome Pubmed: 30560917 |
European Review for Medical and Pharmacological Sciences | Astrocytes induce proliferation of oligodendrocyte progenitor cells via connexin 47-mediated activation of Chi3l1 expression Pubmed: 31002152 |
International journal of molecular sciences | Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients Pubmed: 31717649 |
Research square | Oligodendrocyte Progenitor Cells Increase Chi3l1 Secretion in Exosome to Activate Myh9 and Promote Proliferation through Connexin47 Connected to … |
International Journal of Chronic Obstructive Pulmonary Disease | High Blood Eosinophil and YKL-40 Levels, as Well as Low CXCL9 Levels, are Associated with Increased Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease 33814903 |